| scholarly article | Q13442814 |
| P2093 | author name string | Yao Chen | |
| Xin Wang | |||
| Ming Jiang | |||
| Xiao-Jun Huang | |||
| Lin Liu | |||
| Han-Yun Ren | |||
| Yuan-Bin Wu | |||
| Yong-Rong Lai | |||
| Lan-Ping Xu | |||
| Dai-Hong Liu | |||
| Ling-Hui Xia | |||
| Zi-Min Sun | |||
| Ding-Ming Wan | |||
| Wei-Jun Fu | |||
| Tong-Lin Hu | |||
| P2860 | cites work | International uniform response criteria for multiple myeloma. | Q34549410 |
| Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research | Q35031141 | ||
| Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis | Q35172500 | ||
| Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire | Q35265979 | ||
| Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party | Q36000415 | ||
| Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide | Q37618838 | ||
| Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis | Q38788692 | ||
| Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). | Q39014264 | ||
| T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. | Q39021231 | ||
| T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation | Q39634790 | ||
| Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients | Q44314310 | ||
| Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. | Q44404933 | ||
| Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation | Q44888557 | ||
| Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma | Q45260013 | ||
| Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study | Q45278122 | ||
| Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients | Q46273275 | ||
| Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. | Q46640315 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. | Q48251576 | ||
| Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. | Q50983345 | ||
| Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. | Q52912068 | ||
| Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. | Q53162845 | ||
| Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. | Q54774369 | ||
| Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience | Q69571696 | ||
| Graft-versus-myeloma effect: proof of principle | Q70903400 | ||
| Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome | Q71611831 | ||
| [Allogeneic peripheral blood stem cell transplantation from sibling donors for 10 patients with multiple myeloma] | Q84560229 | ||
| Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free sur | Q84730771 | ||
| T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantati | Q86169061 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 1765-1772 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | Chinese Medical Journal | Q5100534 |
| P1476 | title | Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma | |
| P478 | volume | 132 |
Search more.